Cerevel Therapeutics Holdings, Inc. CERE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

22/100

0/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cerevel Therapeutics Holdings, Inc. (CERE) .

本页证实的标准:

VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($33.50, 25.5%).
分析师共识目标价 $33.50 (-25.5% 下行风险) — 分析师认为当前价格水平存在明显下行风险。

SharesGrow 综合评分： 21/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

22/100

SG Score

View full scorecard →

✗

价值

10/100

Price-to-Earnings & upside

Proven by this page

✗

未來

16/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

健康

50/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

40/100

→ Income

✗

成长

15/100

→ Income

—

收入

N/A

No coverage

估值概览 — CERE

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$-2.67

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

分析师目标价$33.50 (-25.5%)

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2012	$-2.07	$5.37M	$-29.41M	-547.6%
2013	$-2.28	$5.24M	$-32.51M	-620.1%
2014	$-0.81	$2.4M	$-29.32M	-1219.7%
2015	$-4.57	$2.72M	$-28.16M	-1035.1%
2018	$-164.93	$0.00	$-463.64M	-
2019	$-1.01	$0.00	$-128.39M	-
2020	$-2.07	$0.00	$-152.14M	-
2021	$-1.63	$0.00	$-222.45M	-
2022	$-2.32	$0.00	$-351.51M	-
2023	$-2.67	$0.00	$-432.84M	-